pulmonary emphysema

肺気腫 PE

WordNet

1. an abnormal condition of the lungs marked by decreased respiratory function; associated with smoking or chronic bronchitis or old age (同)pulmonary_emphysema

PrepTutorEJDIC

1. 気腫(きしゅ),肺気腫
2. 肺の;肺を冒す

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/07/24 07:47:48」(JST)

wiki en

[Wiki en表示]

Chronic Obstructive Pulmonary Disease
Classification and external resources
Gross pathology of a lung showing centrilobular-type emphysema characteristic of smoking. This close-up of the fixed, cut lung surface shows multiple cavities lined by heavy black carbon deposits.
ICD-10	J40–J44, J47
ICD-9	490–492, 494–496
OMIM	606963
DiseasesDB	2672
MedlinePlus	000091
eMedicine	med/373 emerg/99
MeSH	C08.381.495.389

Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), and chronic obstructive airway disease (COAD), among others, is a type of obstructive lung disease characterized by chronically poor airflow. It typically worsens over time. The main symptoms include shortness of breath, cough, and sputum production. Most people with chronic bronchitis have COPD.

Tobacco smoking is the most common cause of COPD, with a number of other factors such as air pollution and genetics playing a smaller role. In the developing world, one of the common sources of air pollution is from poorly vented cooking and heating fires. Long-term exposure to these irritants causes an inflammatory response in the lungs resulting in narrowing of the small airways and breakdown of lung tissue known as emphysema. The diagnosis is based on poor airflow as measured by lung function tests. In contrast to asthma, the airflow reduction does not improve significantly with the administration of medication.

COPD can be prevented by reducing exposure to the known causes. This includes efforts to decrease rates of smoking and to improve indoor and outdoor air quality. COPD treatments include: quitting smoking, vaccinations, rehabilitation, and often inhaled bronchodilators and steroids. Some people may benefit from long-term oxygen therapy or lung transplantation. In those who have periods of acute worsening, increased use of medications and hospitalization may be needed.

Worldwide, COPD affects 329 million people or nearly 5% of the population. In 2011, it ranked as the fourth-leading cause of death, killing over 3 million people. The number of deaths is projected to increase due to higher smoking rates and an aging population in many countries. It resulted in an estimated economic cost of $2.1 trillion in 2010.

Signs and symptoms

The most common symptoms of COPD are sputum production, shortness of breath and a productive cough. These symptoms are present for a prolonged period of time and typically worsen over time. It is unclear if different types of COPD exist. While previously divided into emphysema and chronic bronchitis, emphysema is only a description of lung changes rather than a disease itself, and chronic bronchitis is simply a descriptor of symptoms that may or may not occur with COPD.

Cough

A chronic cough is usually the first symptom to occur. When it exists for more than three months a year for more than two years, in combination with sputum production and without another explanation, there is by definition chronic bronchitis. This condition can occur before COPD fully develops. The amount of sputum produced can change over hours to days. In some cases the cough may not be present or only occurs occasionally and may not be productive. Some people with COPD attribute the symptoms to a "smoker's cough". Sputum may be swallowed or spat out, depending often on social and cultural factors. Vigorous coughing may lead to rib fractures or a brief loss of consciousness. Those with COPD often have a history of "common colds" that last a long time.

Shortness of breath

Shortness of breath is often the symptom that bothers people the most. It is commonly described as: "my breathing requires effort," "I feel out of breath," or "I can't get enough air in". Different terms, however, may be used in different cultures. Typically the shortness of breath is worse on exertion, of a prolonged duration, and worsens over time. In the advanced stages it occurs during rest and may be always present. It is a source of both anxiety and a poor quality of life in those with COPD. Many people with more advanced COPD breathe through pursed lips and this action can improve shortness of breath in some.

Other features

In COPD, it may take longer to breathe out than to breathe in. Chest tightness may occur but is not common and may be caused by another problem. Those with obstructed airflow may have wheezing or decreased sounds with air entry on examination of the chest with a stethoscope. A barrel chest is a characteristic sign of COPD, but is relatively uncommon. Tripod positioning may occur as the disease worsens.

Advanced COPD leads to high pressure on the lung arteries, which strains the right ventricle of the heart. This situation is referred to as cor pulmonale, and leads to symptoms of leg swelling and bulging neck veins. COPD is more common than any other lung disease as a cause of cor pulmonale. Cor pulmonale has become less common since the use of supplemental oxygen.

COPD often occurs along with a number of other conditions, due in part to shared risk factors. These conditions include: ischemic heart disease, high blood pressure, diabetes mellitus, muscle wasting, osteoporosis, lung cancer, anxiety disorder and depression. In those with severe disease a feeling of always being tired is common. Fingernail clubbing is not specific to COPD and should prompt investigations for an underlying lung cancer.

Exacerbation

An acute exacerbation of COPD is defined as increased shortness of breath, increased sputum production, a change in the color of the sputum from clear to green or yellow, or an increase in cough in someone with COPD. This may present with signs of increased work of breathing such as fast breathing, a fast heart rate, sweating, active use of muscles in the neck, a bluish tinge to the skin, and confusion or combative behavior in very severe exacerbations. Crackles may also be heard over the lungs on examination with a stethoscope.

Cause

The primary cause of COPD is tobacco smoke, with occupational exposure and pollution from indoor fires being significant causes in some countries. Typically these exposures must occur over several decades before symptoms develop. A person's genetic makeup also affects the risk.

Smoking

Percentage of females smoking tobacco as of the late 1990s early 2000s

Percentage of males smoking tobacco as of the late 1990s early 2000s. Note the scales used for females and males differ.

The primary risk factor for COPD globally is tobacco smoking. Of those who smoke about 20% will get COPD, and of those who are lifelong smokers about half will get COPD. In the United States and United Kingdom, of those with COPD, 80-95% are either current smokers or previously smoked. The likelihood of developing COPD increases with the total smoke exposure. Additionally, women are more susceptible to the harmful effects of smoke than men. In non-smokers, secondhand smoke is the cause of about 20% of cases. Other types of smoke, such as marijuana, cigar, and water pipe smoke, also confer a risk. Women who smoke during pregnancy may increase the risk of COPD in their child.

Air pollution

Poorly ventilated cooking fires, often fueled by coal or biomass fuels such as wood and animal dung, lead to indoor air pollution and are one of the most common causes of COPD in developing countries. These fires are a method of cooking and heating for nearly 3 billion people with their health effects being greater among women due to more exposure. They are used as the main source of energy in 80% of homes in India, China and sub-Saharan Africa.

People who live in large cities have a higher rate of COPD compared to people who live in rural areas. While urban air pollution is a contributing factor in exacerbations, its overall role as a cause of COPD is unclear. Areas with poor outdoor air quality, including that from exhaust gas, generally have higher rates of COPD. The overall effect in relation to smoking, however, is believed to be small.

Occupational exposures

Intense and prolonged exposure to workplace dusts, chemicals and fumes increase the risk of COPD in both smokers and nonsmokers. Workplace exposures are believed to be the cause in 10-20% of cases. In the United States they are believed to be related to more than 30% of cases among those who have never smoked and probably represent a greater risk in countries without sufficient regulations.

A number of industries and sources have been implicated, including high levels of dust in coal mining, gold mining, and the cotton textile industry, occupations involving cadmium and isocyanates, and fumes from welding. Working in agriculture is also a risk. In some professions the risks have been estimated as equivalent to that of half to two packs of cigarettes a day. Silica dust exposure can also lead to COPD, with the risk unrelated to that for silicosis. The negative effects of dust exposure and cigarette smoke exposure appear to be additive or possibly more than additive.

Genetics

Genetics play a role in the development of COPD. It is more common among relatives of those with COPD who smoke than unrelated smokers. Currently, the only clearly inherited risk factor is alpha 1-antitrypsin deficiency (AAT). This risk is particularly high if someone deficient in alpha 1-antitrypsin also smokes. It is responsible for about 1-5% of cases and the condition is present in about 3-4 in 10,000 people. Other genetic factors are being investigated, of which there are likely to be many.

Other

A number of other factors are less closely linked to COPD. The risk is greater in those who are poor, although it is not clear if this is due to poverty itself or other risk factors associated with poverty, such as air pollution and malnutrition. There is tentative evidence that those with asthma and airway hyperreactivity are at increased risk of COPD. Birth factors such as low birth weight may also play a role as do a number of infectious diseases including HIV/AIDS and tuberculosis. Respiratory infections such as pneumonia do not appear to increase the risk of COPD, at least in adults.

Exacerbations

An acute exacerbation (a sudden worsening of symptoms) is commonly triggered by infection or environmental pollutants, or sometimes by other factors such as improper use of medications. Infections appear to be the cause of 50 to 75% of cases, with bacteria in 25%, viruses in 25%, and both in 25%. Environmental pollutants include both poor indoor and outdoor air quality. Exposure to personal smoke and secondhand smoke increases the risk. Cold temperature may also play a role, with exacerbations occurring more commonly in winter. Those with more severe underlying disease have more frequent exacerbations: in mild disease 1.8 per year, moderate 2 to 3 per year, and severe 3.4 per year. Those with many exacerbations have a faster rate of deterioration of their lung function. Pulmonary emboli (blood clots in the lungs) can worsen symptoms in those with pre-existing COPD.

Pathophysiology

On the left is a diagram of the lungs and airways with an inset showing a detailed cross-section of normal bronchioles and alveoli. On the right is lungs damaged by COPD with an inset showing a cross-section of damaged bronchioles and alveoli

COPD is a type of obstructive lung disease in which chronic incompletely reversible poor airflow (airflow limitation) and inability to breathe out fully (air trapping) exist. The poor airflow is the result of breakdown of lung tissue (known as emphysema) and small airways disease known as obstructive bronchiolitis. The relative contributions of these two factors vary between people. Severe destruction of small airways can lead to the formation of large air pockets—known as bullae—that replace lung tissue. This form of disease is called bullous emphysema.

Micrograph showing emphysema (left - large empty spaces) and lung tissue with relative preservation of the alveoli (right).

COPD develops as a significant and chronic inflammatory response to inhaled irritants. Chronic bacterial infections may also add to this inflammatory state. The inflammatory cells involved include neutrophil granulocytes and macrophages, two types of white blood cell. Those who smoke additionally have Tc1 lymphocyte involvement and some people with COPD have eosinophil involvement similar to that in asthma. Part of this cell response is brought on by inflammatory mediators such as chemotactic factors. Other processes involved with lung damage include oxidative stress produced by high concentrations of free radicals in tobacco smoke and released by inflammatory cells, and breakdown of the connective tissue of the lungs by proteases that are insufficiently inhibited by protease inhibitors. The destruction of the connective tissue of the lungs is what leads to emphysema, which then contributes to the poor airflow and, finally, poor absorption and release of respiratory gases. General muscle wasting that often occurs in COPD may be partly due to inflammatory mediators released by the lungs into the blood.

Narrowing of the airways occurs due to inflammation and scarring within them. This contributes to the inability to breathe out fully. The greatest reduction in air flow occurs when breathing out, as the pressure in the chest is compressing the airways at this time. This can result in more air from the previous breath remaining within the lungs when the next breath is started, resulting in an increase in the total volume of air in the lungs at any given time, a process called hyperinflation or air trapping. Hyperinflation from exercise is linked to shortness of breath in COPD, as it is less comfortable to breathe in when the lungs are already partly full.

Some also have a degree of airway hyperresponsiveness to irritants similar to those found in asthma.

Low oxygen levels and, eventually, high carbon dioxide levels in the blood can occur from poor gas exchange due to decreased ventilation from airway obstruction, hyperinflation and a reduced desire to breathe. During exacerbations, airway inflammation is also increased, resulting in increased hyperinflation, reduced expiratory airflow and worsening of gas transfer. This can also lead to insufficient ventilation and, eventually, low blood oxygen levels. Low oxygen levels, if present for a prolonged period, can result in narrowing of the arteries in the lungs, while emphysema leads to breakdown of capillaries in the lungs. Both these changes result in increased blood pressure in the pulmonary arteries, which may cause cor pulmonale.

Diagnosis

A person blowing into a spirometer. Smaller handheld devices are available for office use.

The diagnosis of COPD should be considered in anyone over the age of 35 to 40 who has shortness of breath, a chronic cough, sputum production, or frequent winter colds and a history of exposure to risk factors for the disease. Spirometry is then used to confirm the diagnosis.

Spirometry

Spirometry measures the amount of airflow obstruction present and is generally carried out after the use of a bronchodilator, a medication to open up the airways. Two main components are measured to make the diagnosis: the forced expiratory volume in one second (FEV₁), which is the greatest volume of air that can be breathed out in the first second of a breath, and the forced vital capacity (FVC), which is the greatest volume of air that can be breathed out in a single large breath. Normally, 75-80% of the FVC comes out in the first second and a FEV₁/FVC ratio of less than 70% in someone with symptoms of COPD defines a person as having the disease. Based on these measurements, spirometry would lead to over-diagnosis of COPD in the elderly. The National Institute of Clinical Excellence criteria additionally require a FEV₁ of less than 80% of predicted.

Evidence for using spirometry among those without symptoms in an effort to diagnose the condition earlier is of uncertain effect and is therefore currently not recommended. A peak expiratory flow (the maximum speed of expiration), commonly used in asthma, is not sufficient for the diagnosis of COPD.

Severity

MRC shortness of breath scale

Grade	Activity affected
1	Only strenuous activity
2	Vigorous walking
3	With normal walking
4	After a few minutes of walking
5	With changing clothing

GOLD grade

Severity	FEV1 % predicted
Mild (GOLD 1)	≥80
Moderate (GOLD 2)	50–79
Severe (GOLD 3)	30–49
Very severe (GOLD 4)	<30 or chronic respiratory failure

There are a number of methods to determine how much COPD is affecting a given individual. The modified British Medical Research Council questionnaire (mMRC) or the COPD assessment test (CAT) are simple questionnaires that may be used to determine the severity of symptoms. Scores on CAT range from 0–40 with the higher the score, the more severe the disease. Spirometry may help to determine the severity of airflow limitation. This is typically based on the FEV₁ expressed as a percentage of the predicted "normal" for the person's age, gender, height and weight. Both the American and European guidelines recommended partly basing treatment recommendations on the FEV₁. The GOLD guidelines suggest dividing people into four categories based on symptoms assessment and airflow limitation. Weight loss and muscle weakness, as well as the presence of other diseases, should also be taken into account.

Other tests

A chest X-ray and complete blood count may be useful to exclude other conditions at the time of diagnosis. Characteristic signs on X-ray are overexpanded lungs, a flattened diaphragm, increased retrosternal airspace, and bullae while it can help exclude other lung diseases, such as pneumonia, pulmonary edema or a pneumothorax. A high-resolution computed tomography scan of the chest may show the distribution of emphysema throughout the lungs and can also be useful to exclude other lung diseases. Unless surgery is planned, however, this rarely affects management. An analysis of arterial blood is used to determine the need for oxygen; this is recommended in those with an FEV₁ less than 35% predicted, those with a peripheral oxygen saturation of less than 92% and those with symptoms of congestive heart failure. In areas of the world where alpha-1 antitrypsin deficiency is common, people with COPD (particularly those below the age of 45 and with emphysema affecting the lower parts of the lungs) should be considered for testing.

• Chest X-ray demonstrating severe COPD. Note the small heart size in comparison to the lungs.

• A lateral chest x-ray of a person with emphysema. Note the barrel chest and flat diaphragm.

• Lung bulla as seen on CXR in a person with severe COPD

• A severe case of bullous emphysema

• Axial CT image of the lung of a person with end-stage bullous emphysema.

Differential diagnosis

COPD may need to be differentiated from other causes of shortness of breath such as congestive heart failure, pulmonary embolism, pneumonia or pneumothorax. Many people with COPD mistakenly think they have asthma. The distinction between asthma and COPD however cannot be made via spirometry. Tuberculosis may also present with a chronic cough and should be considered in locations where it is common. Less common conditions that may present similarly include bronchopulmonary dysplasia and obliterative bronchiolitis. Chronic bronchitis may occur with normal airflow and in this situation it is not classified as COPD.

Prevention

Most cases of COPD are potentially preventable through decreasing exposure to smoke and improving air quality. Annual influenza vaccinations in those with COPD reduces exacerbations, hospitalizations and death. Pneumococcal vaccination may also be beneficial.

Smoking cessation

Keeping people from starting smoking is a key aspect of preventing COPD. The policies of governments, public health agencies and anti-smoking organizations can reduce smoking rates by discouraging people from starting and encouraging people to stop smoking. Smoking bans in public areas and places of work are important measures to decrease exposure to secondhand smoke and while many places have instituted bans more are recommended.

In those who smoke, stopping smoking is the only measure shown to slow down the worsening of COPD. Even at a late stage of the disease, it can reduce the rate of worsening lung function and delay the onset of disability and death. Smoking cessation starts with the decision to stop smoking, leading to an attempt at quitting. Often several attempts are required before long-term abstinence is achieved. Attempts over 5 years lead to success in nearly 40% of people.

Some smokers can achieve long-term smoking cessation through willpower alone. Smoking, however, is highly addictive, and many smokers need further support. The chance of quitting is improved with social support, engagement in a smoking cessation program and the use of medications such as nicotine replacement therapy, bupropion or varenicline.

Occupational health

A number of measures have been taken to reduce the likelihood that workers in at-risk industries—such as coal mining, construction and stonemasonry—will develop COPD. Examples of these measures include: the creation of public policy, education of workers and management about the risks, promoting smoking cessation, checking workers for early signs of COPD, use of respirators, and dust control. Effective dust control can be achieved by improving ventilation, using water sprays and by using mining techniques that minimize dust generation. If a worker develops COPD, further lung damage can be reduced by avoiding ongoing dust exposure, for example by changing the work role.

Air pollution

Both indoor and outdoor air quality can be improved, which may prevent COPD or slow the worsening of existing disease. This may be achieved by public policy efforts, cultural changes, and personal involvement.

A number of developed countries have successfully improved outdoor quality through regulations. This has resulted in improvements of the lung function of their populations. Those with COPD may experience fewer symptoms if they stay indoors on days when outdoor air quality is poor.

One key effort is to reduce exposure to smoke from cooking and heating fuels through improved ventilation of homes and better stoves and chimneys. Proper stoves may improve indoor air quality by 85%. Using alternative energy sources such as solar cooking and electrical heating is effective, as is using fuels such as kerosene or coal rather than biomass.

Management

There is no known cure for COPD, but the symptoms are treatable and its progression can be delayed. The major goals of management are to reduce risk factors, manage stable COPD, prevent and treat acute exacerbations, and manage associated illnesses. The only measures that have been shown to reduce mortality are smoking cessation and supplemental oxygen. Stopping smoking decreases the risk of death by 18%. Other recommendations include: influenza vaccination once a year, pneumococcal vaccination once every 5 years, and reduction in exposure to environmental air pollution. In those with advanced disease, palliative care may reduce symptoms, with morphine improving the feelings of shortness of breath. Noninvasive ventilation may be used to support breathing.

Exercise

Pulmonary rehabilitation is a program of exercise, disease management and counseling, coordinated to benefit the individual. In those who have had a recent exacerbation, pulmonary rehabilitation appears to improve the overall quality of life and the ability to exercise, and reduce mortality. It has also been shown to improve the sense of control a person has over their disease, as well as their emotions. Breathing exercises in and of themselves appear to have a limited role.

Being either underweight or overweight can affect the symptoms, degree of disability and prognosis of COPD. People with COPD who are underweight can improve their breathing muscle strength by increasing their calorie intake. When combined with regular exercise or a pulmonary rehabilitation program, this can lead to improvements in COPD symptoms. Supplemental nutrition may be useful in those who are malnourished.

Bronchodilators

Inhaled bronchodilators are the primary medications used and result in a small overall benefit. There are two major types, β₂ agonists and anticholinergics; both exist in long-acting and short-acting forms. They reduce shortness of breath, wheeze and exercise limitation, resulting in an improved quality of life. It is unclear if they change the progression of the underlying disease.

In those with mild disease, short-acting agents are recommended on an as needed basis. In those with more severe disease, long-acting agents are recommended. If long-acting bronchodilators are insufficient inhaled corticosteroids are typically added. With respect to long-acting agents, it is unclear if tiotropium (a long-acting anticholinergic) or long-acting beta agonists (LABAs) are better, and it may be worth trying each and continuing the one that worked best. Both types of agent appear to reduce the risk of acute exacerbations by 15-25%. While using both at the same time may offer a benefit, this benefit, if any, is of questionable significance.

There are several short-acting β₂ agonists available including salbutamol (Ventolin) and terbutaline. They provide some relief of symptoms for four to six hours. Long-acting β₂ agonists such as salmeterol and formoterol are often used as maintenance therapy. Some feel the evidence of benefits is limited while others view the evidence of benefit as established. Long-term use appears safe in COPD with adverse effects include shakiness and heart palpitations. When used with inhaled steroids they increase the risk of pneumonia. While steroids and LABAs may work better together, it is unclear if this slight benefit outweighs the increased risks.

There are two main anticholinergics used in COPD, ipratropium and tiotropium. Ipratropium is a short-acting agent while tiotropium is long-acting. Tiotropium is associated with a decrease in exacerbations and improved quality of life, and tiotropium provides those benefits better than ipratropium. It does not appear to affect mortality or the over all hospitalization rate. Anticholinergics can cause dry mouth and urinary tract symptoms. They are also associated with increased risk of heart disease and stroke. Aclidinium, another long acting agent which came to market in 2012, has been used as an alternative to tiotropium.

Corticosteroids

Corticosteroids are usually used in inhaled form but may also be used as tablets to treat and prevent acute exacerbations. While inhaled corticosteroids (ICS) have not shown benefit for people with mild COPD, they decrease acute exacerbations in those with either moderate or severe disease. When used in combination with a LABA they decrease mortality more than either ICS or LABA alone. By themselves they have no effect on overall one-year mortality and are associated with increased rates of pneumonia. It is unclear if they affect the progression of the disease. Long-term treatment with steroid tablets is associated with significant side effects.

Other medication

Long-term antibiotics, specifically those from the macrolide class such as erythromycin, reduce the frequency of exacerbations in those who have two or more a year. This practice may be cost effective in some areas of the world. Concerns include that of antibiotic resistance and hearing problems with azithromycin. Methylxanthines such as theophylline generally cause more harm than benefit and thus are usually not recommended, but may be used as a second-line agent in those not controlled by other measures. Mucolytics may be useful in some people who have very thick mucous but are generally not needed. Cough medicines are not recommended.

Oxygen

Supplemental oxygen is recommended in those with low oxygen levels at rest (a partial pressure of oxygen of less than 50–55 mmHg or oxygen saturations of less than 88%). In this group of people it decreases the risk of heart failure and death if used 15 hours per day and may improve people's ability to exercise. In those with normal or mildly low oxygen levels, oxygen supplementation may improve shortness of breath. There is a risk of fires and little benefit when those on oxygen continue to smoke. In this situation some recommend against its use. During acute exacerbations, many require oxygen therapy; the use of high concentrations of oxygen without taking into account a person's oxygen saturations, may lead to increased levels of carbon dioxide and worsened outcomes. In those at high risk of high carbon dioxide levels, oxygen saturations of 88–92% are recommended, while for those without this risk recommended levels are 94-98%.

Surgery

For those with very severe disease surgery is sometimes helpful and may include lung transplantation or lung volume reduction surgery. Lung volume reduction surgery involves removing the parts of the lung most damaged by emphysema allowing the remaining, relatively good lung to expand and work better. Lung transplantation is sometimes performed for very severe COPD, particularly in younger individuals.

Exacerbations

Acute exacerbations are typically treated by increasing the usage of short-acting bronchodilators. This commonly includes a combination of a short-acting inhaled beta agonist and anticholinergic. These medications can be given either via a metered-dose inhaler with a spacer or via a nebulizer with both appearing to be equally effective. Nebulization may be easier for those who are more unwell.

Oral corticosteroids improve the chance of recovery and decrease the overall duration of symptoms. In those with a severe exacerbation, antibiotics improve outcomes. A number of different antibiotics may be used including: amoxicillin, doxycycline or azithromycin; it is unclear if one is better than the others. There is no clear evidence for those with less severe cases.

Non-invasive positive pressure ventilation in those with acutely raised CO₂ levels (type 2 respiratory failure) decreases the probability of death from or needing intensive care admission for mechanical ventilation. Additionally, theophylline may have a role in those who do not respond to other measures. Less than 20% of exacerbations require hospital admission. In those without acidosis from respiratory failure, home care ("hospital at home") may be able to help avoid some admissions.

Prognosis

Disability-adjusted life year for chronic obstructive pulmonary disease per 100,000 inhabitants in 2004.

  no data

  ≤110

  110–220

  220–330

  330–440

  440–550

  550–660

  660–770

  770–880

  880–990

  990–1100

  1100–1350

  ≥1350

COPD usually gets gradually worse over time and can ultimately result in death. It is estimated that 3% of all disability is related to COPD. The proportion of disability from COPD globally has decreased from 1990 to 2010 due to improved indoor air quality primarily in Asia. The overall number of years lived with disability from COPD, however, has increased.

The rate at which COPD worsens varies with the presence of factors that predict a poor outcome including: severe airflow obstruction, little ability to exercise, shortness of breath, significantly underweight or overweight, congestive heart failure, continued smoking, and frequent exacerbations. Long-term outcomes in COPD can be estimated using the BODE index which gives a score of zero to ten depending on FEV₁, body-mass index, the distance walked in six minutes, and the modified MRC dyspnea scale. Significant weight loss is a bad sign. Results of spirometry are also a good predictor of the future progress of the disease but not as good as the BODE index.

Epidemiology

Globally, as of 2010, COPD affected approximately 329 million people (4.8% of the population) and is slightly more common in men than women. This is as compared to 64 million being affected in 2004. The increase in the developing world between 1970 and the 2000s is believed to be related to increasing rates of smoking in this region, an increasing population and an aging population due to less deaths from other causes such as infectious diseases. Some developed countries have seen increased rates, some have remained stable and some have seen a decrease in COPD prevalence. The global numbers are expected to continue increasing as risk factors remain common and the population continues to get older.

Between 1990 and 2010 the number of deaths from COPD has decreased slightly from 3.1 million to 2.9 million. Overall it is the fourth-leading cause of death. In some countries, mortality has decreased in men but increased in women. This is most likely due to rates of smoking in women and men becoming more similar. COPD is more common in older people; it affects 34-200 out of 1000 people older than 65 years, depending on the population looked at.

In England, an estimated 0.84 million people (of 50 million) have a diagnosis of COPD; translating into approximately one person in 59 receiving a diagnosis of COPD at some point in their lives. In the most socioeconomically deprived parts of the country, one in 32 people were diagnosed with COPD, compared with one in 98 in the most affluent areas. In the United States approximately 6.3% of the adult population, totaling approximately 15 million people, have been diagnosed with COPD. 25 million people may have COPD if currently undiagnosed cases are included. In 2011, there were approximately 730,000 hospitalizations in the United States for COPD.

History

Giambattista Morgagni who made one of the earliest recorded descriptions of emphysema in 1769

The word "emphysema" is derived from the Greek ἐμφυσᾶν emphysan meaning "inflate" -itself composed of ἐν en, meaning "in", and φυσᾶν physan, meaning "breath, blast". The term chronic bronchitis came into use in 1808 while the term COPD is believed to have first been used in 1965. Previously it has been known by a number of different names including: chronic obstructive bronchopulmonary disease, chronic obstructive respiratory disease, chronic airflow obstruction, chronic airflow limitation, chronic obstructive lung disease, nonspecific chronic pulmonary disease, and diffuse obstructive pulmonary syndrome. The terms chronic bronchitis and emphysema were formally defined in 1959 at the CIBA guest symposium and in 1962 at the American Thoracic Society Committee meeting on Diagnostic Standards.

Early descriptions of probable emphysema include: in 1679 by T. Bonet of a condition of "voluminous lungs" and in 1769 by Giovanni Morgagni of lungs which were "turgid particularly from air". In 1721 the first drawings of emphysema were made by Ruysh. These were followed by pictures by Matthew Baillie in 1789 and descriptions of the destructive nature of the condition. In 1814 Charles Badham used "catarrh" to describe the cough and excess mucus in chronic bronchitis. René Laennec, the physician who invented the stethoscope, used the term "emphysema" in his book A Treatise on the Diseases of the Chest and of Mediate Auscultation (1837) to describe lungs that did not collapse when he opened the chest during an autopsy. He noted that they did not collapse as usual because they were full of air and the airways were filled with mucus. In 1842, John Hutchinson invented the spirometer, which allowed the measurement of vital capacity of the lungs. However, his spirometer could only measure volume, not airflow. Tiffeneau and Pinelli in 1947 described the principles of measuring airflow.

Early treatments included garlic, cinnamon and ipecac, among others. Modern treatments were developed during the second half of the 20th century. Evidence supporting the use of steroids in COPD were published in the late 1950s. Bronchodilators came into use in the 1960s following a promising trial of isoprenaline. Further bronchodilators, such as salbutamol, were developed in the 1970s, and the use of LABAs began in the mid-1990s.

Society and culture

See also: COPD Awareness Month

COPD has been referred to as "smoker's lung". Those with emphysema have been known as "pink puffers" or "type A" due to their frequent pink complexion, fast respiratory rate and pursed lips, and people with chronic bronchitis have been referred to as "blue bloaters" or "type B" due to the often bluish color of the skin and lips from low oxygen levels and their ankle swelling. This terminology is no longer accepted as useful as most people with COPD have a combination of both.

Many health systems have difficulty ensuring appropriate identification, diagnosis and care of people with COPD; Britain's Department of Health has identified this as a major issue for the National Health Service and has introduced a specific strategy to tackle these problems.

Economics

Globally, as of 2010, COPD is estimated to result in economic costs of $2.1 trillion, half of which occurring in the developing world. Of this total an estimated $1.9 trillion are direct costs such as medical care, while $0.2 trillion are indirect costs such as missed work. This is expected to more than double in the next 20 years. In Europe, COPD represents 3% of healthcare spending. In the United States, costs of the disease are estimated at $50 billion, most of which is due to exacerbation. COPD was among the most expensive conditions seen in U.S. hospitals in 2011, with a total cost of about $5.7 billion.

Research

See also: COPD: Journal of Chronic Obstructive Pulmonary Disease

Infliximab, an immune-suppressing antibody, has been tested in COPD but there was no evidence of benefit with the possibility of harm. Roflumilast shows promise in decreasing the rate of exacerbations but does not appear to change quality of life. A number of new long acting agents are under development. Treatment with stem cells is being studied. While generally safe and with promising animal data there is little data in humans as of 2014.

Other animals

Chronic obstructive pulmonary disease may occur in a number of other animals and may occur from exposure to cigarette smoke. Most disease, however, is relatively mild. In horses it is also known as recurrent airway obstruction and is typically due to an allergic reaction to straw containing fungus. COPD is commonly found in old dogs.

References

Further reading

• "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Updated 2013". Global Initiative for Chronic Obstructive Lung Disease. Retrieved November 29, 2013. 
• National Institute for Health and Clinical Excellence. Clinical guideline 101: Chronic Obstructive Pulmonary Disease. London, June 2010.
• Qaseem, Amir; Wilt, TJ; Weinberger, SE; Hanania, NA; Criner, G; Van Der Molen, T; Marciniuk, DD; Denberg, T; Schünemann, H; Wedzicha, W; MacDonald, R; Shekelle, P; American College Of, Physicians; American College of Chest Physicians; American Thoracic, Society; European Respiratory, Society (2011). "Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society". Annals of Internal Medicine 155 (3): 179–91. doi:10.7326/0003-4819-155-3-201108020-00008. PMID 21810710. 

External links

• Chronic obstructive pulmonary disease at DMOZ

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 慢性閉塞性肺疾患（COPD）：定義、臨床症状、診断、および病期分類 chronic obstructive pulmonary disease definition clinical manifestations diagnosis and staging
• 2. Management of stable chronic obstructive pulmonary disease
• 3. ドラッグを注射している患者における肺疾患の概要 overview of pulmonary disease in injection drug users
• 4. Management of refractory chronic obstructive pulmonary disease
• 5. 先天性肺葉性肺気腫 congenital lobar emphysema

English Journal

• Clinical phenotypes of obstructive airway diseases in an outpatient population.

• Rootmensen G1,2, van Keimpema A3, Zwinderman A4, Sterk P1.
• The Journal of asthma : official journal of the Association for the Care of Asthma.J Asthma.2016 Dec;53(10):1026-32. doi: 10.3109/02770903.2016.1174258. Epub 2016 Jul 1.
• BACKGROUND AND OBJECTIVES: Historically, obstructive airway diseases such as asthma and COPD are classified as different diseases. Although the definitions are clearly described, classification of patients into these traditional, clinical disease entity can be difficult. Recent evidence that there a
• PMID 27366830

• Steroid-induced resolution of refractory pulmonary interstitial emphysema.

• Mahapatra S1, Scottoline B2.
• The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.J Matern Fetal Neonatal Med.2016 Dec;29(24):4092-5. doi: 10.3109/14767058.2016.1159673. Epub 2016 Mar 29.
• Pulmonary interstitial emphysema (PIE) is a familiar complication of mechanical ventilation in premature infants. Its most severe form, marked by life-threatening respiratory and cardiovascular compromise, is a particularly vexing problem in neonatology. Treatment modalities rely on decubitus positi
• PMID 26952563

• Clinical-Radiologic-Pathologic Correlation of Smoking-Related Diffuse Parenchymal Lung Disease.

• Kligerman S1, Franks TJ2, Galvin JR3.
• Radiologic clinics of North America.Radiol Clin North Am.2016 Nov;54(6):1047-1063. doi: 10.1016/j.rcl.2016.05.010. Epub 2016 Aug 22.
• The direct toxicity of cigarette smoke and the body's subsequent response to this lung injury leads to a wide array of pathologic manifestations and disease states that lead to both reversible and irreversible injury to the large airways, small airways, alveolar walls, and alveolar spaces. These inc
• PMID 27719975

Japanese Journal

• 気腫合併肺線維症の画像と呼吸機能の特徴 (特集 COPDの画像 : 画像と呼吸機能)

• 臼井 裕
• 日本胸部臨床 74(8), 865-871, 2015-08
• NAID 40020553614

• 肺気腫の画像と呼吸機能 (特集 COPDの画像 : 画像と呼吸機能)

• 松岡 伸,齋藤 祐貴,坂元 伸吾 [他]
• 日本胸部臨床 74(8), 838-845, 2015-08
• NAID 40020553560

• Pathological and radiological correlation in an autopsy case of combined pulmonary fibrosis and emphysema

• Karata Hiroki,Tanaka Tomonori,Egashira Ryoko,Tabata Kazuhiro,Otani Kyoko,Hayashi Ryuji,Hori Takashi,Fukuoka Junya
• International Journal of Chronic Obstructive Pulmonary
• … We report an educational autopsy case of combined pulmonary fibrosis and emphysema. … Radiological patterns of the upper lung were considered as mostly emphysema, but pathological observation revealed significant interstitial fibrosis of usual interstitial pneumonia as a major pathology. …
• NAID 120005627354

Related Pictures

---

★リンクテーブル★

リンク元	「肺気腫」「PE」「pneumatosis」
拡張検索	「chronic pulmonary emphysema」
関連記事	「emphysema」「pulmonary」

「肺気腫」

　　[★]

英

emphysema, pulmonary emphysema PE

同

慢性肺気腫 chronic pulmonary emphysema CPE　←　急性肺気腫は存在しない

関

chronic obstructive pulmonary disease

概念

• 肺気腫による気流障害は支持組織としての肺胞が破壊されているため、末梢気道が呼出時に虚脱することと、気道病変の存在による。

定義

• 終末気管支より末梢の気腔が永久的に拡張した状態で、この気腔の壁は破壊されているが線維化はない (1987年アメリカ胸部疾患学会)
• 肺胞壁の破壊的な変化により末梢気管支梢から末梢の含気区域が異常に拡大していることを特徴とする解剖学的変化 (1962 WHO アメリカ胸部疾患学会)

疫学

• 中・高年喫煙者、40歳以上のヘビースモーカーの男子

病型

• 汎小葉型肺気腫 panlobular emphysema
• 小葉中心型肺気腫 centrilobular emphysema
• 傍中隔型肺気腫

症状

• 労作時呼吸困難

• 初期には閉塞性換気障害を認めるが、安静時には症状無し
• 労作時に肺胞の破壊による血管床の減少により、拡散障害による低酸素血症をきたし呼吸困難を呈する。

• 咳嗽・喀痰：慢性気管支炎合併例。肺気腫優位型では、咳嗽・喀痰をあまり訴えないことが多い。

身体所見

参考1改変

• 視診：

• 呼吸促迫時に口すぼめ呼吸、補助呼吸筋(胸鎖乳突筋の発達)
• 胸郭：過膨張、ビヤ樽状、フーバー徴候(呼気時に両側季肋部が内方へ牽引)

• 触診：

• 気管短縮：輪状軟骨から胸骨柄上縁までの距離が2横指以下　　←　　たしか、過膨張により気管支が下方に牽引されるため、だったと思う。

• 打診：

• 胸郭：鼓音

• 聴診

• 肺胞呼吸音の減弱　　←　　たしか、肺胞の破壊のため、だったと思う

検査

動脈血ガス

• PaO2の低下　←　初期には見られない

• 1) 換気-血流比の不均一分布
• 2) 気相内拡散障害
• 3) 肺胞拡散障害

• PaCO2の上昇　→　病状の進展により、PaO2低下、PaCO2上昇しII型呼吸不全となる。これは、気腫の拡張によりガス交換に関与しない空間(死腔)が拡張する結果、死腔換気となり低酸素血症や高炭酸ガス血症を呈する。

肺機能

• 一秒率↓、最大換気量↓、残気量↑
• 残気率 RV/TLC：上昇
• 肺機能検査では、閉塞性障害(FEV1.0%≦70%)を示す。

• 肺実質系の破壊消失　→　肺弾性収縮力の低下　→　気道の呼気閉塞　→↓FEV1.0、↓FEV1.0%
• 残気量は増加するが、肺コンプライアンスの上昇による全肺気量(TLC=VC+RV)の上昇のために肺活量の減少は顕著とならない。

• 換気の不均一分布、DLCOの低下。

参考

• 1.

http://www.naoru.com/haikisyu.htm

「PE」

　　[★]

• pulmonary emphysema 肺気腫
• pulmonary embolism 肺塞栓症
• pericardial effusion 心嚢液 心膜液
• preeclampsia 妊娠高血圧腎症
• pulmonary eosinophilia 肺好酸球増多症
• polyethylene ポリエチレン
• phosphatidylethanolamine ホスファチジルエタノールアミン
• phycoerythrin フィコエリスリン

「pneumatosis」

　　[★]

気腫、肺気腫

関

emphysema、emphysematous、pulmonary emphysema

「chronic pulmonary emphysema」

　　[★] 肺気腫、慢性肺気腫

「emphysema」

　　[★]

• n.

• 気腫
• 肺気腫

• ORIGIN mid 17th cent. (sense 2) : via late Latin from Greek emphusēma, from emphusan ‘puff up.’

• puff upは'息を切らす'

　 　

「pulmonary」

　　[★]

• adj.

• 肺の、肺性の

関

lung、pneumo